Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.30 USD
Change Today +0.30 / 4.29%
Volume 2.7K
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

lightlake therapeutics inc (LLTP) Snapshot

Open
$7.00
Previous Close
$7.00
Day High
$7.50
Day Low
$7.00
52 Week High
02/27/15 - $10.99
52 Week Low
12/4/14 - $3.16
Market Cap
13.5M
Average Volume 10 Days
1.3K
EPS TTM
$-5.28
Shares Outstanding
1.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LIGHTLAKE THERAPEUTICS INC (LLTP)

Related News

No related news articles were found.

lightlake therapeutics inc (LLTP) Related Businessweek News

No Related Businessweek News Found

lightlake therapeutics inc (LLTP) Details

Lightlake Therapeutics Inc., a biopharmaceutical company, focuses on treatments for common addictions and related disorders. It focuses on developing a treatment to reverse opioid overdoses; a treatment for overweight and obese patients with binge eating disorder; and a treatment for patients with bulimia nervosa. The company was formerly known as Madrona Ventures, Inc. and changed its name to Lightlake Therapeutics Inc. in September 2009. Lightlake Therapeutics Inc. was founded in 2005 and is based in New York, New York.

3 Employees
Last Reported Date: 10/27/14
Founded in 2005

lightlake therapeutics inc (LLTP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $452.1K
Executive Chairman
Total Annual Compensation: $324.6K
Chief Financial Officer, Treasurer, Secretary...
Total Annual Compensation: $406.7K
Compensation as of Fiscal Year 2014.

lightlake therapeutics inc (LLTP) Key Developments

Lightlake Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended April 30, 2015

Lightlake Therapeutics Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended April 30, 2015. For the quarter, the company reported revenue of $120,000. Loss from operations was $1,840,418 against $546,941 a year ago. Loss before provision for income taxes was $1,850,695 against $554,195 a year ago. Net loss was $1,850,695 against $554,195 a year ago. Basic and diluted loss per share was $1.01 against $0.31 a year ago. For the nine months, the company reported revenue of $680,000. Loss from operations was $5,370,888 against $7,177,682 a year ago. Loss before provision for income taxes was $5,401,646 against $7,323,141 a year ago. Net loss was $5,401,646 against $7,323,141 a year ago. Basic and diluted loss per share was $2.99 against $4.22 a year ago. Net cash used by operating activities was $3,084,071 against $671,296 a year ago.

Lightlake Therapeutics Inc. Presents at Virtual Investor Conference, Mar-05-2015 11:30 AM

Lightlake Therapeutics Inc. Presents at Virtual Investor Conference, Mar-05-2015 11:30 AM. Speakers: Kevin Pollack, Chief Financial Officer, Treasurer, Secretary and Director, Roger Crystal, Chief Executive Officer, President and Director.

Arvind Agrawal Joins Lightlake Therapeutics Inc. as Executive Vice President, Medical Affairs

Lightlake Therapeutics Inc. announced that Arvind Agrawal has joined the company as Executive Vice President, Medical Affairs, effective January 2015. Mr. Agrawal brings over 20 years of experience in medical and public affairs, scientific communications, and clinical development to Lightlake. During his career, Mr. Agrawal has overseen, managed, and delivered global phase I-IV clinical studies and has extensive experience in the therapeutic areas of addiction, psychiatry, CNS, respiratory, cardiovascular, and diabetes. Prior to joining Lightlake, Mr. Agrawal was Head of Medical Affairs New Products at Mundipharma International, where he made significant advances in the development of a novel treatment for opioid addiction.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLTP:US $7.30 USD +0.30

LLTP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LLTP.
View Industry Companies
 

Industry Analysis

LLTP

Industry Average

Valuation LLTP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGHTLAKE THERAPEUTICS INC, please visit www.lightlaketherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.